Sameer Chopra, Head of Clinical Development at Werewolf Therapeutics, shared on LinkedIn:
“We are grateful to the SITC 2026 organizers for awarding Werewolf Therapeutics a late-breaking oral presentation for WTX-124 (IL-2) and a poster presentation for WTX-330 (IL-12).
The data from our completed Phase 1 studies in cancer patients show that it is possible to engineer cytokines to be preferentially activated in the solid tumor microenvironment even upon systemic (IV) administration.
This prodrug engineering strategy has eliminated the life-threatening toxicities that have plagued IL-2 and IL-12 therapies historically, but without compromising their potent clinical antitumor activity.
These are early days, but we hope to advance the development of these promising molecules on behalf of the many cancer patients who are in need of safe and effective new immunotherapies.”
Read the full announcement:
You may also be interested in:
NK Cell Therapies, AI-Driven Advances and the Future of Cancer Immunotherapy at SITC 2026 – CRI
Sandra Demaria: Who Is Shaping the Future of Cancer Immunotherapy at SITC 2026?
Samik Upadhaya: SITC 2026 Sparks New Ideas Across the Evolving Landscape of Cancer Immunotherapy